Literature DB >> 6145515

The clinical and hemodynamic effects of propranolol, pindolol and verapamil in the treatment of exertional angina pectoris.

D L Johnston, D E Manyari, W J Kostuk.   

Abstract

The efficacy of two beta-receptor antagonists, propranolol and pindolol, was compared with that of a calcium antagonist, verapamil, in the treatment of exertional angina pectoris in 22 men (mean age 51 years). The clinical response and left ventricular function were evaluated with treadmill exercise and with radionuclide ventriculography performed while the patient was at rest or exercising supine with a bicycle ergometer. All the treatments significantly prolonged exercise duration (p less than 0.001) and reduced the number of patients terminating treadmill exercise because of angina (p less than 0.05). The resting heart rate was decreased markedly (p less than 0.001) by propranolol but only slightly (p less than 0.05) by pindolol and verapamil. The left ventricular ejection fraction during rest was unchanged by any treatment, but that during exercise was improved (p less than 0.05) by all the treatments. Patients who failed to gain relief from angina with one of the drugs often responded to another, and adverse reactions occurring with one drug did not necessarily occur with another. In summary, pindolol and verapamil were safe and effective alternatives to propranolol in the treatment of the exertional angina pectoris of these patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145515      PMCID: PMC1483318     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  30 in total

1.  Letter: Grading of angina pectoris.

Authors:  L Campeau
Journal:  Circulation       Date:  1976-09       Impact factor: 29.690

2.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a beta-adrenoreceptor blocker.

Authors:  W Frishman; R Silverman; J Strom; U Elkayam; E Sonnenblick
Journal:  Am Heart J       Date:  1979-08       Impact factor: 4.749

3.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity.

Authors:  W Frishman; J Kostis; J Strom; M Hossler; U Elkayam; S Goldner; R Silverman; R Davis; J Weinstein; E Sonnenblick
Journal:  Am Heart J       Date:  1979-10       Impact factor: 4.749

4.  Improvement of exercise-induced left ventricular dysfunction with oral propranolol in patients with coronary heart disease.

Authors:  A Battler; J Ross; R Slutsky; M Pfisterer; W Ashburn; V Froelicher
Journal:  Am J Cardiol       Date:  1979-08       Impact factor: 2.778

5.  Intrinsic sympathomimetic activity in relation to the precipitation of heart failure by beta-adrenoceptive blockade.

Authors:  A M Barrett; B Nunn
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-01

6.  Verapamil in angina: a double-blind trial.

Authors:  D N Phear
Journal:  Br Med J       Date:  1968-06-22

7.  Effect of propranolol on left ventricular function, segmental wall motion, and diastolic pressure-volume relation in man.

Authors:  J Coltart; E L Alderman; S C Robison; D C Harrison
Journal:  Br Heart J       Date:  1975-04

8.  The localization of coronary artery stenoses by 12 lead ECG response to graded exercise test: support for intercoronary steal.

Authors:  D Robertson; W J Kostuk; S P Ahuja
Journal:  Am Heart J       Date:  1976-04       Impact factor: 4.749

9.  Dose response effectiveness of propranolol for the treatment of angina pectoris.

Authors:  E L Alderman; R O Davies; J J Crowley; M G Lopes; J Z Brooker; J P Friedman; A F Graham; H J Matlof; D C Harrison
Journal:  Circulation       Date:  1975-06       Impact factor: 29.690

10.  Effects of intravenous verapamil on hemodynamics in patients with heart disease.

Authors:  B N Singh; A H Roche
Journal:  Am Heart J       Date:  1977-11       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.